Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
51 verified discoveries match your filters.
In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and…
Primary source cited
Last reviewed
In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with…
Primary source cited
Last reviewed
In cohort 1 of the single-arm, phase 2b HERIZON-BTC-01 trial, zanidatamab -- a bispecific antibody that binds two separate sites on the HER2 protein -- produced a confirmed objective response…
Primary source cited
Last reviewed
In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the…
Primary source cited
Last reviewed
In the LIBRETTO-121 trial's primary efficacy population of 25 pediatric and young adult patients with RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, selpercatinib…
Primary source cited
Last reviewed
In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9…
Primary source cited
Last reviewed
FAST-02 is a single-arm feasibility trial testing proton FLASH radiotherapy -- an experimental technique that delivers a full course of radiation in under 1 second, more than 100 times faster…
Primary source cited
Last reviewed
In two separate, randomized, double-blind, phase 3 trials (SPOTLIGHT and GLOW), adding zolbetuximab to first-line chemotherapy significantly extended both progression-free survival and overall survival, compared with chemotherapy alone, in patients…
Primary source cited
Last reviewed
In the prospective, single-arm, phase 2 ROBOCOLO trial, robotic-assisted surgery for resectable right-sided colon cancer met its primary safety endpoint (postoperative complication rate within 30 days), supporting robotic surgery as…
Primary source cited
Last reviewed
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
Primary source cited
Last reviewed